Delandistrogene moxeparvovec-rokl
SRP-9001-305
Phase 3 small_molecule active
Quick answer
Delandistrogene moxeparvovec-rokl for Duchenne Muscular Dystrophy is a Phase 3 program (small_molecule) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sarepta Therapeutics
- Indication
- Duchenne Muscular Dystrophy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active